
News|Videos|June 4, 2015
Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
Author(s)Dung T. Le, MD
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Advertisement
In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Tazemetostat Withdrawn From Follicular Lymphoma, Sarcoma Markets
2
Treating Young Patients With Colorectal Cancer: Talking With a Surgeon
3
FDA Issues CRL for Retifanlimab/Chemotherapy in Metastatic NSCLC
4
Dismantling Barriers to Early Adoption of Bispecifics in Multiple Myeloma
5
























































